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NON-MELANOMA SKIN CANCER IN RENAL TRANSPLANT
RECIPIENTS: DO WE STILL OVERLOOK IT?
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Non-melanoma skin cancer (NMSC) is the most frequent cancer in renal transplant recipients (RTRs). Clini-
cal and epidemiological studies indicate that long-life immunosuppressive therapy that is essential for pre-
venting graft rejection and obtaining adequate graft function after renal transplantation, combined with older 
age at transplantation, total sun burden during life, fair skin type and personal history of treated NMSC before 
transplantation, are the most important risk factors for NMSC development. Since RTRs are more suscep-
tible to developing more aggressive types of skin cancers, especially squamous cell carcinoma (SCC), it is 
of great importance to develop cancer awareness in these patients, making them sensitive to sun protection 
and regular dermatologic and skin self-examination. Immunosuppressive therapy as a risk factor of high 
importance has to be individually tailored and, if necessary, altered in order to decrease cancer formation 
as much as possible, while preserving graft survival and function. Therefore, interdisciplinary approach, in-
cluding primarily nephrologists and dermatologists, should be employed in follow up of RTRs, thus enabling 
prevention, early diagnosing and appropriate treatment of NMSC in these patients.
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INTRODuCTION
Renal transplantation is nowadays established as the 
best therapeutic approach for end-stage renal failure, 
enabling patients to abandon chronic dialysis and to get 
prolonged life span and better quality of life. After trans-
plantation, patients require lifelong immunosuppressive 
treatment which prevents graft rejection, but also in-
creases the risk of various complications including op-
portunistic infections and malignancy development(1). 
Additionally, there is increased mortality for a given 
stage and grade of malignancy compared with patients 
not receiving immunosuppressants. 
It has been estimated that organ transplant recipients 
(OTRs) have a three- to six-fold increased risk of devel-
oping solid organ cancer or internal malignancy com-
pared to the normal population2. Non-melanoma skin 
cancer (NMSC) is the most common cancer in renal 
transplant recipients (RTRs). Other malignant skin tu-
mors such as malignant melanoma, Kaposi’s sarcoma, 
Merkel cell cancer, sebaceous carcinoma and cutaneous 
lymphoma occur less frequently in RTRs, but still at a 
greater frequency than in the non-immunosuppressed 
populations(3).
EPIDEMIOLOGY
Several studies indicate that up to 40% of OTRs devel-
op precancerous skin growths such as actinic keratosis 
and Bowen’s disease (squamous cell carcinoma in situ), 
as well as NMSC within the first 5 years after trans-
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plantation(4). NMSC develops most frequently, account-
ing for 90% of all skin cancers in OTRs(5). It is well 
established that immunosuppressed patients develop 
NMSC more often and much earlier than immunocom-
petent people(2). Furthermore, it has been estimated 
that immunosuppressive therapy carries a 65-fold in-
creased risk of squamous cell carcinoma (SCC) and 10 
to 16-fold increased risk of basal cell carcinoma (BCC) 
development compared to immunocompetent popula-
tion(6). These data show that the risk of BCC increases 
linearly, whereas the risk of SCC increases exponen-
tially.
The incidence of skin cancer among RTRs has been 
differently estimated, varying from 2% to 30%(3,7-11). 
These differences could probably be ascribed to dif-
ferent amount of sun exposure in different populations. 
Most studies indicate that SCC is predominant to BCC 
in RTRs, with an SCC/BCC ratio of 3:1, which is re-
versed compared to the normal(10,12-14). However, a mi-
nor number of studies found BCC to be the most com-
mon carcinoma in RTRs(7,15,16), which is consistent with 
data in the general population(17). In addition, some au-
thors found similar frequency of both (SCC/BCC ratio 
1.1:1)(18). 
RISK FACTORS 
Remarkable advances in immunosuppressive therapy 
have led to longer survival of RTRs, which is associ-
ated with an increased risk of developing more aggres-
sive skin cancers. Therefore, there is an urgent need to 
identify patients that are at the greatest risk of aggres-
sive (metastatic) skin cancer.
Several risk factors have been identified to contribute 
to actuating cutaneous carcinogenesis in RTRs, includ-
ing age, overall uV exposure, Fitzpatrick skin type, 
personal history of previous non-melanoma skin can-
cer and immunosuppressive therapy. The cause of renal 
insufficiency, HLA mismatch, blood type or RH factor 
do not seem to influence cancer formation(9,16), nor does 
the pretransplant dialysis period(9).
AGE
Older age at transplantation has been found as a risk 
factor for NMSC development in RTRs(12,14). In the 
RTRs transplanted after age 55, the risk ratio for NMSC 
was 12-fold higher than in RTRs that were younger 
than 34 at the time of transplantation. This increasing 
prevalence in older age can be explained by the higher 
cumulative uV dose, an important risk factor for SCC 
development, in both immunocompetent and immuno-
suppressed population. Consistent to these data is the 
finding that OTRs that had been transplanted at the 
age of approximately 40 years developed skin tumors 
within a mean of 8 years, whereas ORTs that were older 
than 60 at the time of transplantation developed skin 
tumors within a mean of 3 years. This can be explained 
by the higher incidence of preclinical skin tumors in 
older age, which are additionally promoted by immu-
nosuppressive therapy. 
uLTRAVIOLET RADIATION
In the general population, the major risk factor for BCC 
development is intensive sun exposure in childhood and 
adolescence, while for SCC chronic cumulative sun ex-
posure and ultraviolet (uV) cell damage is assumed(17). 
Consistently, in RTRs uV exposure is also considered 
to be an important risk factor for NMSC development. 
SCC in RTRs is mostly located on sun exposed body 
areas such as the face, ears and hands, supporting the 
uV damage being a risk factor(19). Namely, uV rays to-
gether with immunosuppressants alter skin immunity, 
which leads to the absence of recognition of tumor an-
tigens and tumor initiation. 
FITZPATRICK SKIN TYPE
up to 89% of RTRs with NMSC have been classi-
fied by Fitzpatrick into type I, II or III(13). The risk ra-
tio for cutaneous SCC in OTRs with Fitzpatrick skin 
type I-II has been estimated to be 65-fold to 250-fold 
higher when compared with immunocompetent popu-
lation(20-22).
PERSONAL HISTORY
Immunocompetent patients who develop NMSC have 
a 10-fold increased incidence of subsequent NMSC 
development (3-year cumulative risk for development 
of second NMSC is 18% for SCC and 44% for BCC) 
comparing to people who do not have personal history 
of NMSC23. It has been estimated that RTRs with one 
NMSC have a 49-times higher risk of subsequent can-
cer formation compared to the matched control group(24). 
usually, SCC arises in so called “field cancerization”, 
an area of previous great actinic damage and epidermal 
dysplasia. Therefore, RTRs who developed one SCC 
will carry a greater risk of subsequent skin cancer for-
mation, already taking into consideration the burden of 
immunosuppression. Prior use of biologic therapy or a 
history of leukemia or lymphoma carries an additional 
risk of NMSC development in RTRs(19).
IMMuNOSuPPRESSIVE THERAPY
The risk rate for NMSC development in OTRs is strongly 
related not only to the intensity and duration of immuno-
suppression, but also to the type of immunosuppressive 
therapy. Induction therapy is introduced before, at the 
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time of, or immediately after transplantation induction. 
It includes biologic agents such as lymphocyte-depleting 
agents or interleukin-2 receptor agonist (IL2-RA). In 
heart transplant recipients, it has been shown that in-
duction therapy consisting of antithymocyte globulin, 
OKT3 or monoclonal anti-IL-2 receptor antibodies car-
ries an increased risk of NMSC development(25). Initial 
and long term maintenance immunosuppressive therapy 
is introduced primarily to prevent acute graft rejection 
and to obtain adequate graft function. Introduction of 
calcineurin inhibitors Cyclosporin A and tacrolimus to 
the former double immunosuppressive protocol consist-
ing of prednisone and antiproliferative drug (azathio-
prine and mycophenolate mofetil) has ameliorated graft 
survival. However, posttransplant cancer formation is 
the major problem connected to long and aggressive im-
munosuppression.
All immunosuppressive drugs may enhance cancer de-
velopment, but the greatest risk has been attributed to 
azathioprine and Cyclosporin A. Photosensitivity and 
actuated photocarcinogenesis induced by azathioprine 
are caused by the interaction between DNA 6-thiogua-
nine and uVA(26,27). There are indications that PTCH 
gene mutations in BCC may also be associated with 
azathioprine use, particularly with cancers on non-sun-
exposed skin areas(28). Laboratory experiments suggest 
that Cyclosporin A inhibits mitochondrial permeabil-
ity transition pore (MPTP) opening and prohibits ke-
ratinocyte cell death caused by genotoxic stress, thus 
promoting skin cancer development. No such effects 
were observed with the use of mycophenolate mofetil 
or tacrolimus(29,30). When comparing azathioprine, cy-
closporine and tacrolimus therapy regarding the risk of 
NMSC development, studies are contradictory. Some 
authors found a higher incidence of NMSC in patients 
having received cyclosporine than in those treated with 
azathioprine or tacrolimus(31-33), whereas others found no 
significant difference between the patients having re-
ceived cyclosporine or azathioprine therapy(14,34,35).
Additionally, studies showed that triple immunosuppres-
sive therapy (cyclosporine, prednisone, and azathioprine 
or sirolimus) posed a greater risk of NMSC than dual 
therapy (prednisone and azathioprine or sirolimus), and 
that maintenance monotherapy with calcineurin inhibi-
tor, cyclosporin A or tacrolimus, after stabilization of 
graft function diminished the risk of cancer develop-
ment(36).
Based on the above-mentioned studies, it has been pro-
posed that maintenance protocol should be based on 
mycophenolate mofetil and low-dose calcineurin in-
hibitor Cyclosporin A or tacrolimus, with or without 
prednisone. Recent evidence suggests that novel immu-
nosuppressive therapy, mammalian target of rapamycin 
(mTOR) inhibitors (sirolimus and everolimus) prevents 
skin cancer formation(37,38). Even though the use of novel 
immunosuppressive drugs and their exact impact on 
skin cancer prevention is not fully established, high risk 
patients, patients with previous NMSC and patients with 
potential metastatic spread of a skin cancer may benefit 
from switch to the new models of immunosuppression.
PROGNOSIS OF NMSC IN RTRS
Generally, BCC grows slowly, but if untreated, it can 
grow to a great extent, destroying the underlying tissues 
down through the bone. Opposed to BCC, SCC shows a 
potential for metastatic dissemination. It has been esti-
mated that 6% of immunocompetent patients with SCC 
have a metastatic disease, which is connected with poor 
long-term prognosis. 
For dermatologists who deal with skin cancers and for 
nephrologists who are following RTRs, the ability to 
recognize patients with a more aggressive type of skin 
cancer is of great importance. There are several factors 
in SCC which may point to a more aggressive type of 
SCC. Location of cancer on the ear and lip, history of 
previously treated SCC, size of more than 2 cm, depth of 
more than 4 mm, poor cell differentiation and perineural 
invasion are considered to mark SCC with greatest 
chance of recurrence, while all these signs in combina-
tion with immunosuppression may serve as a prognostic 
marker for metastatic cancer spreading(39).
Sometimes, histologic findings alone are not enough. 
Therefore, there is a comprehensive search for a single 
biomarker which will be able to recognize more aggres-
sive SCC. It is known that tumor suppressor gene p53 
regulates cell response to genotoxic stress, including uV 
cell damage(40). Inactivation of both p53 gene alleles pro-
motes surviving of genetically damaged cells and thus 
promotes cancer formation(41). Immunohistochemical 
analysis of the p53 expression pattern is being used as a 
marker of gene mutation and inactivation(42). In immuno-
suppressed patients, a higher intensity of p53 expression 
pattern has been found(19). The level of serine protease 
inhibitor clade A member 1’s (SerpinA1 or alpha -1-an-
titrypsin) expression pattern was elevated in SCC of 
bullous epidermolysis patients. These patients develop 
more aggressive skin cancers as a result of mutual ac-
tion of chronic skin inflammation, skin ulceration, uV 
exposure and immunosuppression(43). The role of matrix 
metalloproteinase 7 (MMP7) in SCC progression has 
been suggested, as up-regulation of MMP7 has been de-
tected in SCC(44). 
THERAPY
As NMSC are most frequent cancers in RTRs, show-
ing a tendency to more rapid progression than in im-
munocompentent individuals, close monitoring of these 
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patients, preventive measures and early treatment are 
mandatory. Patients should be educated, even before 
transplantation, about the impact of uV radiation and 
immunosuppression drugs on the skin, as well as about 
mandatory compliance with sun protection and using 
both protective clothes and sunscreens. Education on 
regular skin self-examination is as important as derma-
tological follow up. 
Actinic keratoses and small and superficial SCC should 
be early and aggressively treated by cryotherapy, topi-
cally with 5-fluorouracil cream, imiquimod cream or 
photodynamic therapy in order to prevent progression 
to invasive SCC. Lesions suspected of transition to in-
vasive SCC should be biopsied as early as possible and 
treated. Although electrodesiccation and curettage may 
achieve acceptable curative rate, surgical excision with 
clear margins is more advisable. Mohs’ micrographic 
surgery is appropriate for high risk areas. If surgical 
excision is not curative, adjuvant radiation therapy may 
be performed. Whether sentinel lymph node biopsy 
(SLNB) is a mandatory procedure in high risk patients 
or just close lymph node monitoring is sufficient, is still 
being debated, especially as there are no clear criteria for 
SLNB enrolment(24).
High risk patients, including those with metastatic SCC 
and patients who develop multiple SCCs (5-10 per year) 
may benefit from adjuvant systemic retinoid therapy. 
Retinoid use is both chemoprotective and serves as adju-
vant therapy, but cannot replace monitoring and surgical 
treatment. Retinoid therapy is usually life-long, as recur-
rences have been observed after drug discontinuation19.
When chemoprotection and sun protection methods are 
not enough or are contraindicated, switch to a different 
immunosuppressive regimen is preferred.
CONCLuSION 
Renal transplantation promotes longer and prosperous 
life of patients with chronic renal failure. Chronic immu-
nosuppression needed for graft survival goes along with 
complications such as infection and cancer development, 
with skin SCC being the most frequent one. Stronger and 
longer duration of immunosuppression, combined with 
older age at transplantation, uV radiation, fair skin color 
and history of NMSC before transplantation contribute 
to skin SCC development. Moreover, SCC in RTRs car-
ries a tendency to aggressiveness and higher morbidity 
and mortality than in immunocompetent patients. RTRs 
should be educated about the increased risk of cancer 
development, the importance of skin self-examination 
and need for early detection, diagnosis and initiation of 
appropriate treatment. Therefore, interdisciplinary ap-
proach to these patients is recommended, bringing to-
gether nephrologists and dermatologists, surgeons, pa-
thologists and oncologists. Interdisciplinary cooperation 
together with further scientific advances in the fields of 
transplantation and dermato-oncology should help us 
identify the group of RTRs with a tendency of develop-
ing invasive SCC, so that they can be put under more 
regular and careful supervision. 
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SAŽETAK
NEMELANOMSKI KARCINOM KOŽE u PRIMATELJA BuBREŽNOG
PRESATKA – PROPušTAMO LI TO JOš uVIJEK?
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Nemelanomski karcinomi kože najčešći su karcinomi u bolesnika s transplantiranim bubregom. Kliničke i 
epidemiološke studije ukazuju na to da su najvažniji čimbenici rizika za razvoj nemelanomskih karcinoma 
kože doživotna imunosupresivna terapija nužna za sprječavanje odbacivanja presatka i održanje njegove 
funkcije te starija životna dob bolesnika prilikom transplantacije, izloženost UV zrakama tijekom života, svje-
tliji tipovi kože i osobna anamneza preboljelog karcinoma kože prije transplantacije. Budući da su bolesnici 
s transplantiranim bubregom skloniji razvoju agresivnijih tipova kožnih karcinoma, osobito planocelularnog 
karcinoma, izrazito je važno razviti svijest bolesnika s transplantatom o povećanoj sklonosti razvoju karcino-
ma kože, potrebi za prevencijom te redovitim dermatološkim pregledima i samopregledima kože. Imunosu-
presivnu terapiju treba prilagoditi svakom pojedinom bolesniku te ju po potrebi modificirati kako bi se smanjio 
rizik za pojavu karcinoma uz istodobno održanje funkcije presatka. Za praćenje bolesnika s transplantiranim 
bubregom potreban je interdisciplinarni pristup uključujući primarno nefrologe i dermatologe kako bismo 
omogućili bolesnicima s transplantatom prevenciju, ranu dijagnozu i odgovarajuće liječenje karcinoma kože
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Z. Bukvić Mokos, T. Borlinić, N. Bašić-Jukić, P. Kea, I. Mokos. Non-melanoma skin cancer in renal transplant recipients:
do we still overlook it? Acta Med Croatica, Vol. 70 (2016) (Suppl. 2) 59-64
